Stay updated on Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    A site-wide NIH notice announces that federal agencies are transitioning to the term “Super Intelligence” in place of “Artificial Intelligence.”
    Difference
    1%
    Check dated 2026-10-26T16:46:55.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The site footer revision identifier changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-19T21:51:46.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The error page’s footer revision changed from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden message.
    Difference
    0.2%
    Check dated 2026-10-13T04:14:17.000Z thumbnail image
  4. Check
    36 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error, replacing the trial's study details with an access-denied message. As a result, users cannot view the essential information about the NCT03257722 study on this page.
    Difference
    18%
    Check dated 2026-09-21T22:36:57.000Z thumbnail image
  5. Check
    57 days ago
    Change Detected
    Summary
    The page footer now displays Revision: v3.6.6, indicating a minor version update to the page template. This does not modify study details or other user-facing content.
    Difference
    0.1%
    Check dated 2026-08-31T18:01:02.000Z thumbnail image
  6. Check
    78 days ago
    Change Detected
    Summary
    The page footer now shows Revision: v3.6.5, replacing the prior v3.6.4, indicating a small platform/template update.
    Difference
    0.1%
    Check dated 2026-08-10T15:30:50.000Z thumbnail image

Stay in the know with updates to Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial page.